PHYSIOLOGIC CHANGES IN COAGULATION AND FIBRINOLYSIS DURING NORMAL PREGNANCY

Clinics in Liver Disease

Volumn 3, Issue 1, 1999, Pages 83-96

  Deitcher, Steven R ^a   Gardner, Janie F ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; FIBRONECTIN; KALLIKREIN; KININOGEN; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOCYTE FACTOR 4; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ANTIGEN DETECTION; ARTICLE; BLOOD CLOTTING; FIBRIN MESH FORMATION; FIBRINOLYSIS; FIRST TRIMESTER PREGNANCY; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; KALLIKREIN KININ SYSTEM; LIFESPAN; MEDICAL PARAMETERS; PLATELET PLUG FORMATION; PLATELET REACTIVITY; PREGNANCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PUERPERIUM; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBUS; VASCULAR ENDOTHELIUM;

EID: 85013272353     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70055-6     Document Type: Article

References (53)

1. 1 Adam, A., Albert, A., Boulanger, J., et al. Influence of oral contraceptives and pregnancy on constituents of the kallikrein-kininogen system in plasma. Clin Chem, 31, 1985, 1533.
2. 2 Andersson, A., Huiltberg, B., Brattstrom, L., et al. Decreased serum homocysteine in pregnancy. Eur J Clin Chem Clin Biochem, 30, 1992, 377.
3. 3 Andersson, T., Lorentzen, B., Hogdahl, H., et al. Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res, 82, 1996, 109.
4. 4 Bauer, K.A., Rosenberg, R.D., Congenital antithrombin III deficiency: Insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation. Am J Med, 87, 1989, 39.
5. 5 Bellart, J., Gilabert, R., Fontcuberta, J., et al. Fibrinolysis changes in normal pregnancy. J Perinat Med, 25, 1997, 368.
6. 6 Berrettini, M., Malaspina, M., Parise, P., et al. A simple chromogenic substrate assay of tissue factor pathway inhibitor activity in plasma and serum. Am J Clin Pathol, 103, 1995, 391.
7. 7 Bertina, R., Koeleman, B., Koster, T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 1994, 64.
8. 8 Bontis, J., Vavilis, D., Agorastos, T., et al. Maternal plasma level of thrombomodulin is increased in mild preeclampsia. Eur J Obstet Gynecol Reprod Biol, 60, 1995, 139.
9. 9 Bremme, K., Ostlund, E., Almqvist, I., et al. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and puerpium. Obstet Gynecol, 80, 1992, 132.
10. 10 Cerneca, F., Ricci, G., Simeone, R., et al. Coagulation and fibrinolysis changes in normal pregnancy: Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with fibrinolysis. Eur J Obstet Gynecol Reprod Biol, 73, 1997, 31.
11. 11 Clarke, R., Daly, L., Robinson, K., et al. Hyperhomocysteinemia—an independent risk factor for vascular disease. N Engl J Med, 324, 1991, 1149.
12. 12 Comeglio, P., Fedi, S., Liotta, A.A., et al. Blood clotting activation during pregnancy. Thromb Res, 84, 1996, 199.
13. 13 Comp, P.C., Overview of the hypercoagulable states. Semin Thromb Hemost, 16, 1990, 158.
14. 14 Comp, P.C., Thurnau, G.R., Welsh, J., et al. Functional and immunologic protein S levels are decreased during pregnancy, delivery, and the puerperium. Blood, 68, 1986, 881.
15. 15 Coppola, R., Cristilli, P., Cugno, M., et al. Measurement of activated factor XII in health and disease. Blood Coagul Fibrinolysis, 7, 1996, 530.
16. 16 Dalaker, K., Prydz, H., The coagulation factor VII in pregnancy. Br J Haematol, 56, 1983, 233.
17. 17 Delorme, M., Burrows, R., Ofosu, F., et al. Thrombin regulation in mother and fetus during pregnancy. Semin Thromb Hemost, 18, 1992, 81.
18. 18 De Moerloose, P., Amiral, J., Vissac, A.-M., et al. Longitudinal study on activated factors XII and VII levels during normal pregnancy. Br J Haematol, 100, 1998, 40.
19. 19 Deng, L., Bremme, K., Hansson, L.O., et al. Plasma levels of von Willebrand factor and fibronectin as markers of persisting endothelial damage in preeclampsia. Obstet Gynecol, 84, 1994, 941.
20. 20 Ewenstein, B.M., Von Willebrand's disease. Annu Rev Med, 48, 1997, 525.
21. 21 Francalanci, I., Comeglio, P., Liotta, A.A., et al. D-Dimer concentrations during normal pregnancy, as measured by ELISA. Thromb Res, 78, 1995, 399.
22. 22 Gatti, L., Tenconi, P.M., Guarneri, D., et al. Hemostatic parameters and platelet activation by flow cytometry in normal pregnancy: A longitudinal study. Int J Clin Lab Res, 24, 1994, 217.
23. 23 Gerbasi, F.R., Bottoms, S., Farag, A., et al. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol, 75, 1990, 385.
24. 24 Girolami, A., Marafioti, F., Rubertelli, M., et al. Congenital heterozygous plasminogen deficiency associated with a severe thrombotic tendency. Acta Haematol, 75, 1986, 54.
25. 25 Halligan, A., Bonnar, J., Sheppard, B., et al. Hemostatic, fibrinolytic and endothelial variables in normal pregnancy and preeclampsia. Br J Obstet Gynecol, 101, 1994, 448.
26. 26 Kakkar, A.K., DeRuvo, N., Chinswangwatanakul, V., et al. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet, 346, 1995, 1004.
27. 27 Konijnenberg, A., Stokkers, E.W., van der Post, J.A.M., et al. Extensive platelet activation in preeclampsia compared with normal pregnancy: Enhanced expression of cell adhesion molecules. Am J Obstet Gynecol, 176, 1997, 461.
28. 28 Koster, T., Blann, A.D., Bri et, E., et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet, 345, 1995, 152.
29. 29 Krishnamurti, C., Alving, B.M., Plasminogen activator inhibitor type 1: Biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost, 18, 1992, 67.
30. 30 Lee, M.H., Vosburgh, E., Anderson, K., et al. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood, 81, 1993, 2357.
31. 31 Lefkowitz, J.B., Clarke, S.H., Barbour, L.A., Comparison of protein S functional and antigenic assays in normal pregnancy. Am J Obstet Gynecol, 175, 1996, 657.
32. 32 Mammen, E.F., Barnhart, M.I., Selik, N.R., et al. “Sticky platelet syndrome”: A congenital platelet abnormality predisposing to thrombosis?. Folia Haematol Int Mag Klin Morphol Blutforsch, 115, 1988, 361.
33. 33 Mutoh, S., Kobayashi, M., Hirata, J., et al. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium. Agents Actions, 38(suppl), 1992, 320.
34. 34 Nakashima, A., Kobayashi, T., Terao, T., Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors. Gynecol Obstet Invest, 42, 1996, 95.
35. 35 Nilsson, I.M., Kullander, S., Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynecol Scand, 46, 1967, 273.
36. 36 Paternoster, D., Stella, A., Simioni, P., et al. Clotting inhibitors and fibronectin as potential markers in preeclampsia. Int J Gynaecol Obstet, 47, 1994, 215.
37. 37 Phillips, L.L., Rosano, L., Skrodelis, V., Changes in factor XI (plasma thromboplastin antecedent) levels during pregnancy. Am J Obstet Gynecol, 116, 1973, 1114.
38. 38 Reinthaller, A., Murch-Edlmayr, G., Tatra, G., Thrombin-antithrombin III complex in normal pregnancy with hypertensive disorders and after delivery. Br J Obstet Gynecol, 97, 1990, 506.
39. 39 Romero, R., Snyder, E., Scott, D., et al. Beta-thromboglobulin during normal pregnancy, labor, and puerperium. Am J Perinat, 5, 1988, 109.
40. 40 Schlit, A.-F., Col-de Beys, C., Moriau, E., et al. Acquired activated protein C resistance in pregnancy. Thromb Res, 84, 1996, 203.
41. 41 Singer, C.R., Walker, J.J., Cameron, A., et al. Platelet studies in normal pregnancy and pregnancy-induced hypertension. Clin Lab Haematol, 8, 1986, 27.
42. 42 Sorenson, J.D., Secher, N.J., Jespersen, J., Perturbed (procoagulant) endothelium and deviations within the fibrinolytic system during the third trimester of pregnancy. Acta Obstet Gynecol, 74, 1995, 257.
43. 43 Star, J., Rosene, K., Ferland, J., et al. Flow cytometric analysis of platelet activation throughout normal gestation. Obstet Gynecol, 90, 1997, 562.
44. 44 Stirling, Y., Woolf, L., North, W.R.S., et al. Haemostasis in normal pregnancy. Thromb Haemost, 52, 1984, 176.
45. 45 Svensson, P.J., Dahlback, B., Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med, 330, 1994, 517.
46. 46 Tei, A., Mutoh, S., Yaoi, Y., et al. Serum levels of coagulation-fibrinolysis factors in normal pregnancy, labor and puerium and in cesarean section delivery. Bulletin of the Tokyo Medical and Dental University, 36, 1997, 13.
47. 47 Thompson, S.G., Kienast, J., Pyke, S., et al., for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group, Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med, 332, 1995, 635.
48. 48 Tygart, S.G., McRoyan, D.K., Spinnato, J.A., et al. Longitudinal study of platelet indices during normal pregnancy. Am J Obstet Gynecol, 154, 1986, 883.
49. 49 Van Wersch, J.W.J., Vooijs, M.E.E.C., Ubachs, J.M.H., Coagulation factor XIII in pregnant smokers and non-smokers. Int J Clin Lab Res, 27, 1997, 68.
50. 50 Walker, M.C., Garner, P.R., Keely, E.J., et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol, 177, 1997, 162.
51. 51 Wallenburg, H.C., van Kessel, P.H., Platelet lifespan in normal pregnancy as determined by a nonradioisotopic technique. Br J Obstet Gynaecol, 85, 1978, 33.
52. 52 Williams, E.C., Plasma alpha 2-antiplasmin activity: Role in the evaluation and management of fibrinolytic states and other bleeding disorders. Arch Intern Med, 149, 1989, 1769.
53. 53 Wiman, B., Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease. Thromb Haemost, 74, 1995, 71.